Studies analysing decay kinetics of HIV-1-RNA in SP with InSTI-based regimens
| First author . | n . | Backbone . | Third drug . | Basal SP HIV-1-RNA log10 copies/mL . | Undetectable SP HIV-1-RNA at Week 12 (%) . |
|---|---|---|---|---|---|
| Imaz15 | 15 | ABC/3TC | Dolutegravir | 3.91 [2.97–4.82] | 93.3 |
| Gutierrez-Valencia10 | 12 | TDF/FTC | Elvitegravir | 3.88 [3.01–5.72] | 100 |
| Imaz18 | 15 | TAF/FTC | Bictegravir | 3.54 (2.41–3.79) | 100 |
| Fabrizio16 | 18 | TDF/FTC or ABC/3TC | Dolutegravir | 2.82 (1.89–3.13) | 72.3 |
| Fernandez-González17 | 12 | ABC/3TC | Dolutegravir | 4.11 (3.60–4.44) | 58.3 |
| Ghosn12 | 19 | TDF/FTC | Dolutegravir | 4.50 [2.70–5.90] | 80.0 |
| Mariaggi13 | 12 | TDF/FTC | Dolutegravir | 5.22 [3.45–6.21] | 42.0 |
| Current study | 15 | TAF/FTC | Dolutegravir | 3.34 (2.70–3.56) | 93.3 |
| 14 | 3TC | 3.80 (2.86–5.37) | 92.9 |
| First author . | n . | Backbone . | Third drug . | Basal SP HIV-1-RNA log10 copies/mL . | Undetectable SP HIV-1-RNA at Week 12 (%) . |
|---|---|---|---|---|---|
| Imaz15 | 15 | ABC/3TC | Dolutegravir | 3.91 [2.97–4.82] | 93.3 |
| Gutierrez-Valencia10 | 12 | TDF/FTC | Elvitegravir | 3.88 [3.01–5.72] | 100 |
| Imaz18 | 15 | TAF/FTC | Bictegravir | 3.54 (2.41–3.79) | 100 |
| Fabrizio16 | 18 | TDF/FTC or ABC/3TC | Dolutegravir | 2.82 (1.89–3.13) | 72.3 |
| Fernandez-González17 | 12 | ABC/3TC | Dolutegravir | 4.11 (3.60–4.44) | 58.3 |
| Ghosn12 | 19 | TDF/FTC | Dolutegravir | 4.50 [2.70–5.90] | 80.0 |
| Mariaggi13 | 12 | TDF/FTC | Dolutegravir | 5.22 [3.45–6.21] | 42.0 |
| Current study | 15 | TAF/FTC | Dolutegravir | 3.34 (2.70–3.56) | 93.3 |
| 14 | 3TC | 3.80 (2.86–5.37) | 92.9 |
Basal SP HIV-1-RNA expressed as median (IQR) median [range] log10 copies/mL.
Studies analysing decay kinetics of HIV-1-RNA in SP with InSTI-based regimens
| First author . | n . | Backbone . | Third drug . | Basal SP HIV-1-RNA log10 copies/mL . | Undetectable SP HIV-1-RNA at Week 12 (%) . |
|---|---|---|---|---|---|
| Imaz15 | 15 | ABC/3TC | Dolutegravir | 3.91 [2.97–4.82] | 93.3 |
| Gutierrez-Valencia10 | 12 | TDF/FTC | Elvitegravir | 3.88 [3.01–5.72] | 100 |
| Imaz18 | 15 | TAF/FTC | Bictegravir | 3.54 (2.41–3.79) | 100 |
| Fabrizio16 | 18 | TDF/FTC or ABC/3TC | Dolutegravir | 2.82 (1.89–3.13) | 72.3 |
| Fernandez-González17 | 12 | ABC/3TC | Dolutegravir | 4.11 (3.60–4.44) | 58.3 |
| Ghosn12 | 19 | TDF/FTC | Dolutegravir | 4.50 [2.70–5.90] | 80.0 |
| Mariaggi13 | 12 | TDF/FTC | Dolutegravir | 5.22 [3.45–6.21] | 42.0 |
| Current study | 15 | TAF/FTC | Dolutegravir | 3.34 (2.70–3.56) | 93.3 |
| 14 | 3TC | 3.80 (2.86–5.37) | 92.9 |
| First author . | n . | Backbone . | Third drug . | Basal SP HIV-1-RNA log10 copies/mL . | Undetectable SP HIV-1-RNA at Week 12 (%) . |
|---|---|---|---|---|---|
| Imaz15 | 15 | ABC/3TC | Dolutegravir | 3.91 [2.97–4.82] | 93.3 |
| Gutierrez-Valencia10 | 12 | TDF/FTC | Elvitegravir | 3.88 [3.01–5.72] | 100 |
| Imaz18 | 15 | TAF/FTC | Bictegravir | 3.54 (2.41–3.79) | 100 |
| Fabrizio16 | 18 | TDF/FTC or ABC/3TC | Dolutegravir | 2.82 (1.89–3.13) | 72.3 |
| Fernandez-González17 | 12 | ABC/3TC | Dolutegravir | 4.11 (3.60–4.44) | 58.3 |
| Ghosn12 | 19 | TDF/FTC | Dolutegravir | 4.50 [2.70–5.90] | 80.0 |
| Mariaggi13 | 12 | TDF/FTC | Dolutegravir | 5.22 [3.45–6.21] | 42.0 |
| Current study | 15 | TAF/FTC | Dolutegravir | 3.34 (2.70–3.56) | 93.3 |
| 14 | 3TC | 3.80 (2.86–5.37) | 92.9 |
Basal SP HIV-1-RNA expressed as median (IQR) median [range] log10 copies/mL.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
